Clinical trials
Myasthenia Gravis clinical trials
Below are recruiting myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06540144Enrolling by invitationPhase 3
Extended rozanolixizumab treatment for children with myasthenia gravis
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
BolognaAges 2 years+ - NCT05374590Enrolling by invitationPhase 2/Phase 3
Long-term safety study of efgartigimod for young myasthenia gravis patients
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
Chicago, IllinoisAges 2–18 - NCT06463587RecruitingPhase 3
Oral cladribine for generalized myasthenia gravis
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Phoenix, ArizonaAges 18 years+ - NCT06006832Recruiting
A Study of Myasthenia Gravis in China
This study follows people with myasthenia gravis who are patients at Peking Union Medical College Hospital to learn more about the disease and how it affects patients over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06987539RecruitingPhase 2
Inebilizumab for children with generalized myasthenia gravis
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
Austin, TexasAges 2–17 - NCT07058298RecruitingEarly Phase 1
GC012F injection for hard-to-treat myasthenia gravis
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Wuhan, HubeiAges 18–75 - NCT07215650RecruitingPhase 1
Cizutamig for generalized myasthenia gravis
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07413835Recruiting
Study of HN2302 for hard-to-treat myasthenia gravis
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Xuzhou, JiangsuAges 18–80 - NCT06241521Recruiting
Myasthenia gravis patient registry in China
This study creates a registry to collect information about people with myasthenia gravis in China. By joining, you help researchers learn more about the condition and how it affects different people.
Beijing, Beijing MunicipalityAges Any age - NCT06456580RecruitingPhase 3
Telitacicept for generalized myasthenia gravis
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Scottsdale, ArizonaAges 18 years+ - NCT06815133Recruiting
Study of zilucoplan in French patients with myasthenia gravis
This trial is for people in France with myasthenia gravis who are already taking zilucoplan. It tracks how well and how safely the medicine works over 3 months in everyday practice.
Nice, Alpes MaritimesAges 18 years+ - NCT06909214RecruitingPhase 4
Study of efgartigimod for new-onset generalized myasthenia gravis
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
La Jolla, CaliforniaAges 18 years+ - NCT04535843Recruiting
Precision testing study for myasthenia gravis in China
This study follows people with suspected or confirmed myasthenia gravis (a condition that causes muscle weakness that gets worse with use). It uses several specialized nerve and antibody tests to make a more precise diagnosis and tracks you over time to see how well these methods work.
Shanghai, Shanghai MunicipalityAges birth–90 years - NCT06587867RecruitingPhase 3
Efgartigimod for seronegative myasthenia gravis
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
Toronto, OntarioAges 18 years+ - NCT06754020Recruiting
Traditional Chinese tongue diagnosis for myasthenia gravis
This study uses tongue imaging and traditional Chinese medicine methods to compare tongue features between people with myasthenia gravis and healthy individuals. It may help understand how tongue diagnosis relates to this condition.
New Taipei City, Tamsui DistrictAges 20 years+ - NCT07221838RecruitingPhase 4
Steroid Tapering Study for Myasthenia Gravis on Ravulizumab
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
Chicago, IllinoisAges 18 years+ - NCT07595653Recruiting
Efgartigimod Treatment Experience in Generalized Myasthenia Gravis
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Acquaviva delle FontiAges 18 years+ - NCT07247279Recruiting
Study of myasthenia gravis treatments in Russia
This study tracks how generalized myasthenia gravis (a condition that causes muscle weakness) is treated in Russia. By looking at real-world data, researchers hope to learn more about which treatments work best for people like you.
Kazan'Ages 18 years+ - NCT04182984Recruiting
Compare immunosuppressant medicines for eye-only myasthenia gravis
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
Xi'an, ShaanxiAges 18–75 - NCT06866652Recruiting
Why Am I Short of Breath? A Study in Myasthenia Gravis
This study looks at why people with myasthenia gravis (MG) feel short of breath. It aims to understand breathing problems that happen in daily life, even when MG seems stable.
ParisAges 18 years+ - NCT07072988RecruitingPhase 4
Steroid reduction with efgartigimod in older adults with generalized myasthenia gravis
This trial tests if a new drug called efgartigimod can help older adults with generalized myasthenia gravis safely reduce their steroid dose. The goal is to manage the disease with fewer steroid side effects.
Nice, Alpes-MaritimesAges 65 years+ - NCT07217509Enrolling by invitation
Myasthenia gravis drug safety registry
This study tracks the safety and effectiveness of newer drugs for myasthenia gravis. If you have started or are about to start a new medication for MG, this registry can help doctors learn more about how well these treatments work in real life.
Waltham, MassachusettsAges 18 years+ - NCT04202341Recruiting
Registry for people with generalized myasthenia gravis on Alexion treatment
This study is a registry, meaning it collects health and disease information from people with generalized myasthenia gravis (gMG) who are receiving Alexion C5 “inhibition” therapies. Your data can help researchers better understand real-world outcomes and disease patterns over time.
Birmingham, AlabamaAges 18 years+ - NCT06866483Recruiting
Online screening for undiagnosed myasthenia gravis
This study tests a new online screening tool to find people who might have undiagnosed myasthenia gravis (a muscle-weakness condition). You answer questions about your symptoms and get more information if the tool suggests you might need to talk to a doctor.
Evanston, IllinoisAges 18 years+
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myasthenia gravis?
- Yes. Clin2 currently lists 105 recruiting myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.